Industry news that matters to you.  Learn more

QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient’s tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

FDA Approves New Blood Test to Improve Prostate Cancer Detection

Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5 times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.

Parsortix Research Partnership with the Paterson Institute for Cancer Research

ANGLE plc (AIM: AGL) is pleased to announce that Parsortix Inc (“Parsortix”), its 90% owned portfolio company which specialises in cancer diagnostics, has signed a two year research agreement with the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester’s world-leading cancer research institute.

FDA Clears Critical Diagnostics Presage ST2 Assay for Patients with Heart Failure

Critical Diagnostics is a U.S.-based biomarker company focused on optimizing patient care in cardiovascular diseases, such as heart failure. The San Diego-based company announced yesterday that they have received FDA approval for their Presage ST2 Assay for use as an aid in assessing the prognosis of patients diagnosed with chronic heart failure [1].

Name You Need To Know in 2011: The S100B Blood Test

It has been coined the signature wound of the Iraq war. Traumatic brain injury has been on the rise as improvised explosive devices in Iraq and Afghanistan expose troops to more blasts and resultant head wounds than ever before.